DSP Healthcare Fund Direct Growth
Equity
Direct
Sector - Healthcare
NAV as on 19-11-2024
₹ 44.19
▲0.8%
1D
Inception Returns
28.3%
/yr
About DSP Healthcare Fund Direct Growth
DSP Healthcare Fund Direct Growth is an equity fund. This fund was started on 30 November, 2018. The fund is managed by Chirag Dagli, Jay Kothari. The fund could potentially beat inflation in the long-run.
Key Parameters
- DSP Healthcare Fund Direct Growth has ₹3138 Cr worth of assets under management (AUM) as on Oct 2024 and is more than category average.
- The fund has an expense ratio 0.6.
Returns
DSP Healthcare Fund Direct Growth has given a CAGR return of 28.25% since inception. Over the last 1, 3 and 5 years the fund has given a CAGR return of 48.88%, 22.94% and 32.68% respectively.
Holdings
DSP Healthcare Fund Direct Growth has allocated its funds majorly in Cash Equivalent, Health, Financial Services. Its top holdings are Sun Pharmaceuticals Industries Ltd, Suven Pharmaceuticals Ltd, Ipca Laboratories Ltd, Cipla Ltd, Illumina Inc
Taxation
As it is a sector - healthcare mutual fund the taxation is as follows:For short term (less than a year) capital gains will be taxed at 15%For long term (more than 1 year) capital gains will be taxed at 10% without indexation benefitDividends will always be taxed at slab rate. Gains upto Rs 1 lakh are exempt in case of long term.
Investment objective of DSP Healthcare Fund Direct Growth
The primary investment objective of the scheme is to seek to generate consistent returns by predominantly investing in equity and equity related securities of pharmaceutical and healthcare companies. However, there can be no assurance that the investment objective of the scheme will be realized.
Minimum Investment and lockin period
Minimum investment for lump sum payment is INR 100.00 and for SIP is INR 100.00. DSP Healthcare Fund Direct Growth has no lock in period.
Historical NAV & Returns
Annualised
▲
▼
6549 people have invested ₹ 4.8Cr in DSP Healthcare Fund Direct Growth in the last three months
INDmoney Rank for DSP Healthcare Fund Direct Growth
Powered by IND quant engine
IND ranking is not available for this fund.
5Y returns in the top 25% of the category
3Y returns in the top 25% of the category
Among most bought funds within the category
No bad points found for this fund.
DSP Healthcare Fund Direct Growth Overview
| Expense ratio | 0.59% |
Benchmark | S&P BSE Healthcare PR |
| AUM | ₹3138 Cr |
| Inception Date | 30 November, 2018 |
| Min Lumpsum/SIP | ₹100/₹100 |
Exit Load | 0.5% |
| Lock In | No Lock-in |
TurnOver | 17.89% |
| STCG | Redeeming before 1 year, returns taxed at 20%. |
| LTCG | After 1 year, 12.5% tax on returns over ₹1.25 lakh/year. |
| Risk |   Very High Risk |
Trailing Returns
as on (19-Nov-24)
Fund Distribution
as on (31-Oct-24)
Small cap
40.3%
Large cap
22.1%
Mid cap
18.5%
Sector Allocation
Health
98.5%
Financial Services
1.5%
All changes are between Aug'24 and Oct'24
- This fund’s returns stands at -0.09% whereas the fund’s underlying benchmark Nifty 500 returns stands at -6.52% as on Oct'24
- This fund outperformed Nifty 500 by 6.43% in Oct'24
- AUM of the fund stands at 3.1K Cr as of Oct'24
- AUM increased by 44.4 Cr between Oct'24 and Sep'24
Top Stocks bought last month
Gland Pharma Ltd's allocation increased from 2.07% to 4.33%
Suven Pharmaceuticals Ltd's allocation increased from 9.8% to 10.82%
Emcure Pharmaceuticals Ltd's allocation increased from 0.77% to 1.57%
Top Stocks sold last month
Sun Pharmaceuticals Industries Ltd's allocation decreased from 11.68 % to 11.05 %
Cipla Ltd's allocation decreased from 7.41 % to 6.85 %
Alembic Pharmaceuticals Ltd's allocation decreased from 5.55 % to 5.12 %
Large Cap allocation has gone down from 23.4% to 22.1%
Small Cap allocation has gone up from 38.2% to 40.3%
Mid Cap allocation has gone down from 20% to 18.5%
Cash allocation has gone down from 3.3% to 2.7%
Top 2 Sectors in October were Health, Financial Services
Oct'24
Health
98%
Financial Services
2%
Sep'24
Health
98%
Financial Services
2%
Holdings | Weight% | 1M Change | |
|---|---|---|---|
 Sun Pharmaceuticals Industries Ltd | 11.05% | 0% | |
 Suven Pharmaceuticals Ltd | 10.82% | 0% | |
 Ipca Laboratories Ltd | 8.12% | 0% | |
 Cipla Ltd | 6.85% | 0% | |
 Illumina Inc | 5.38% | 0% |
See all
See all
Top Growth Drivers | 1M Return |
|---|---|
 Unichem Laboratories Ltd | 16.3% |
 Suven Pharmaceuticals Ltd | 0.2% |
Loading...
We are taking more time than usual
Chirag Dagli
Fund Manager of DSP Healthcare Fund Direct Growth, since 1 December 2020
Top funds managed
Jay Kothari
Fund Manager of DSP Healthcare Fund Direct Growth, since 30 November 2018
Top funds managed
Fund House
DSP Asset Managers Private Limited
Total Schemes
Total AUM
₹1.28L Cr
as on 30-Sep-2023
Address
India
Phone
91-22-66578000
Website
service@dspblackrock.com
Mutual Fund Insights
In the last 1 year, HDFC Pharma and Healthcare Fund Direct Growth has given 52.89% return, outperforming this fund by 4%.
In the last 5 years, this fund has outperformed all funds in its category.
In the last 3 years, ICICI Prudential Pharma Healthcare and Diagnostics (P.H.D) Fund Direct Growth has given 24.29% return, outperforming this fund by 1.35% per annum.
Over the last 1 year, this fund has decreased expense ratio by 18.1% moving from 0.72 to 0.59.
Over the last 6 months, this fund has experienced a 33.9% growth in AUM moving from 2.34K Cr to 3.13K Cr.
This fund has one of the lowest expense ratio in the category (sector - healthcare). Its expense ratio is 0.59% which is lower than the category average expense ratio of 1.39%.
DSP Healthcare Fund Direct Growth Highlights
Very High Risk
Investors understand that their principal will be at Very High Risk
About the fund
This fund has delivered an average annual returns of 28.25% since inception which is more than its category average return of 24.96%
Fund Allocations
This fund has an allocation of 97.28% in Equity, 0% in Debt and 2.72% in Cash related instruments
AUM size ₹3138 Cr
This fund has AUM of ₹3138 Cr which is more than its category average of ₹ 2001 Cr
Expense Ratio 0.59%
This fund has an expense ratio of 0.59% which is less than its category average expense ratio of 1.33%
Frequently Asked Questions for DSP Healthcare Fund Direct Growth
The current NAV of DSP Healthcare Fund Direct Growth is ₹44.19 as on 19-Nov-2024.
Existing (Absolute + CAGR) as on 19-Nov-2024.
DSP Healthcare Fund Direct Growth | Absolute Returns | CAGR Returns |
1 Month Returns | -1.98% | -1.98% |
6 Month Returns | 23.75% | 23.75% |
1 Year Returns | 48.88% | 48.88% |
3 Years Returns | 85.81% | 22.94% |
5 Years Returns | 311.16% | 32.68% |
With INDmoney, the process of investing is very simple and involves zero commission.
- Click Buy on the fund name.
- Input the amount you are looking to invest.
- Select Lump Sum or SIP (Weekly, Monthly or Quarterly).
- Select your bank account and proceed with Payment.
0.59% as on October 2024
₹3138 Cr as on October 2024
Sun Pharmaceuticals Industries Ltd(11.05%), Suven Pharmaceuticals Ltd(10.82%), Ipca Laboratories Ltd(8.12%), Cipla Ltd(6.85%), Illumina Inc(5.38%) as on October 2024
The alpha ratio for the DSP Healthcare Fund Direct Growth for various period is as follows:
Fund Name | Alpha 1 Year | Alpha 3 Years | Alpha 5 Years |
DSP Healthcare Fund Direct Growth | 0.45 | 2.74 | 7.74 |
As on October 2024
The alpha for DSP Healthcare Fund Direct Growth is calculated against S&P BSE Healthcare PR. Higher alpha indicates that this fund has generated extra returns compared to the benchmark index. An alpha of 1.0 means the fund has outperformed its benchmark index by 1%.
The Beta ratio for the DSP Healthcare Fund Direct Growth for various period is as follows:
Fund Name | Beta 1 Year | Beta 3 Years | Beta 5 Years |
DSP Healthcare Fund Direct Growth | 0.97 | 0.93 | 0.8 |
As on October 2024
The Beta for DSP Healthcare Fund Direct Growth is calculated with S&P BSE Healthcare PR. Beta tells the volatility of the mutual fund relative to its benchmark. If the beta of a mutual fund is more than 1, then the mutual fund is more volatile than its benchmark. If beta is less than 1, then the mutual fund is less volatile than the benchmark.
The sharpe ratio for the DSP Healthcare Fund Direct Growth for various period is as follows:
Fund Name | Sharpe Ratio 1 Year | Sharpe Ratio 3 Years | Sharpe Ratio 5 Years |
DSP Healthcare Fund Direct Growth | 2.89 | 1.07 | 1.48 |
As on October 2024
The sharpe ratio for DSP Healthcare Fund Direct Growth is calculated with S&P BSE Healthcare PR. Sharpe ratio tells risk-adjusted-returns of the mutual fund. The higher a fund's Sharpe ratio, the better a fund's returns have been relative to the risk it has taken on.
The standard deviation for the DSP Healthcare Fund Direct Growth for various period is as follows:
Fund Name | Standard Deviation 1 Year | Standard Deviation 3 Years | Standard Deviation 5 Years |
DSP Healthcare Fund Direct Growth | 14.67 | 15.55 | 16.97 |
As on October 2024
Standard deviation tells the volatility of the returns of the mutual fund. The higher a fund's Standard deviation, the higher the volatility of the fund's returns.
Sortino ratio is 2.06 as on October 2024. Sortino ratio tells the downside risk-adjusted-returns of the mutual fund.
Information ratio is 0.44 as on October 2024. It tells the consistency of the fund in generating superior risk-adjusted performance
Chirag Dagli, Jay Kothari are the fund managers of DSP Healthcare Fund Direct Growth
The Exit load of DSP Healthcare Fund Direct Growth is 0.5%